Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics (VKTX) stock plunges and short sellers betting against the company gain $521M amid the selloff. Read more here.

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Find insight on Viking Therapeutics, CSL and more in the latest Market Talks covering the health care sector..

Nasdaq futures dipped a further 0.4% after investors sold AI tech stocks yesterday, leading to a near-1.5% daily decline, though the index is still up 40% since April's low. Palantir ( PLTR -9.39%) ...